181 related articles for article (PubMed ID: 38332874)
1. Retinoblastoma vulnerability to combined
Mollick T; Darekar S; Dalarun B; Plastino F; Zhang J; Fernández AP; Alkasalias T; André H; Laín S
Heliyon; 2024 Jan; 10(1):e23831. PubMed ID: 38332874
[TBL] [Abstract][Full Text] [Related]
2. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer.
Mullen NJ; Thakur R; Shukla SK; Chaika NV; Kollala SS; Wang D; He C; Fujii Y; Sharma S; Mulder SE; Sykes DB; Singh PK
Cancer Lett; 2023 Jan; 552():215981. PubMed ID: 36341997
[TBL] [Abstract][Full Text] [Related]
3. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022).
Gehlot P; Vyas VK
Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M
PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894
[TBL] [Abstract][Full Text] [Related]
5. The Role of Dihydroorotate Dehydrogenase in Apoptosis Induction in Response to Inhibition of the Mitochondrial Respiratory Chain Complex III.
Khutornenko AA; Dalina AA; Chernyak BV; Chumakov PM; Evstafieva AG
Acta Naturae; 2014 Jan; 6(1):69-75. PubMed ID: 24772329
[TBL] [Abstract][Full Text] [Related]
6. Proof-of-principle studies on a strategy to enhance nucleotide imbalance specifically in cancer cells.
Alkasalias T; Zhang J; Madapura H; Dalarun B; Reina OB; Lewensohn R; Viktorsson K; Salihi A; Darekar S; Laín S
Cell Death Discov; 2022 Nov; 8(1):464. PubMed ID: 36424385
[TBL] [Abstract][Full Text] [Related]
7. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
[TBL] [Abstract][Full Text] [Related]
8. Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia.
Branstrom A; Cao L; Furia B; Trotta C; Santaguida M; Graci JD; Colacino JM; Ray B; Li W; Sheedy J; Mollin A; Yeh S; Kong R; Sheridan R; Baird JD; O'Keefe K; Spiegel R; Goodwin E; Keating S; Weetall M
Front Oncol; 2022; 12():832816. PubMed ID: 35223511
[TBL] [Abstract][Full Text] [Related]
9. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
[TBL] [Abstract][Full Text] [Related]
10. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.
Sexauer AN; Alexe G; Gustafsson K; Zanetakos E; Milosevic J; Ayres M; Gandhi V; Pikman Y; Stegmaier K; Sykes DB
Blood Adv; 2023 Nov; 7(21):6685-6701. PubMed ID: 37648673
[TBL] [Abstract][Full Text] [Related]
11. Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication.
Luganini A; Sibille G; Mognetti B; Sainas S; Pippione AC; Giorgis M; Boschi D; Lolli ML; Gribaudo G
Antiviral Res; 2021 May; 189():105057. PubMed ID: 33716051
[TBL] [Abstract][Full Text] [Related]
12. Modulating pyrimidine ribonucleotide levels for the treatment of cancer.
Mollick T; Laín S
Cancer Metab; 2020; 8():12. PubMed ID: 33020720
[TBL] [Abstract][Full Text] [Related]
13. DHODH and cancer: promising prospects to be explored.
Zhou Y; Tao L; Zhou X; Zuo Z; Gong J; Liu X; Zhou Y; Liu C; Sang N; Liu H; Zou J; Gou K; Yang X; Zhao Y
Cancer Metab; 2021 May; 9(1):22. PubMed ID: 33971967
[TBL] [Abstract][Full Text] [Related]
14. The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia.
Gaidano V; Houshmand M; Vitale N; Carrà G; Morotti A; Tenace V; Rapelli S; Sainas S; Pippione AC; Giorgis M; Boschi D; Lolli ML; Cilloni D; Cignetti A; Saglio G; Circosta P
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33670894
[TBL] [Abstract][Full Text] [Related]
15. DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation.
Mullen NJ; Shukla SK; Thakur R; Kollala SS; Wang D; Chaika N; Santana JF; Miklavcic WR; LaBreck DA; Mallareddy JR; Price DH; Natarajan A; Mehla K; Sykes DB; Hollingsworth MA; Singh PK
bioRxiv; 2024 Jan; ():. PubMed ID: 37066260
[TBL] [Abstract][Full Text] [Related]
16. Discovery of small molecule inhibitors of human uridine-cytidine kinase 2 by high-throughput screening.
Okesli-Armlovich A; Gupta A; Jimenez M; Auld D; Liu Q; Bassik MC; Khosla C
Bioorg Med Chem Lett; 2019 Sep; 29(18):2559-2564. PubMed ID: 31420268
[TBL] [Abstract][Full Text] [Related]
17. The Warburg effect modulates DHODH role in ferroptosis: a review.
Amos A; Amos A; Wu L; Xia H
Cell Commun Signal; 2023 May; 21(1):100. PubMed ID: 37147673
[TBL] [Abstract][Full Text] [Related]
18. Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
Demarest JF; Kienle M; Boytz R; Ayres M; Kim EJ; Patten JJ; Chung D; Gandhi V; Davey RA; Sykes DB; Shohdy N; Pottage JC; Kumar VS
Antiviral Res; 2022 Oct; 206():105403. PubMed ID: 36041646
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a new pyrimidine synthesis inhibitor eradicating glioblastoma-initiating cells.
Echizenya S; Ishii Y; Kitazawa S; Tanaka T; Matsuda S; Watanabe E; Umekawa M; Terasaka S; Houkin K; Hatta T; Natsume T; Maeda Y; Watanabe SI; Hagiwara S; Kondo T
Neuro Oncol; 2020 Feb; 22(2):229-239. PubMed ID: 31499527
[TBL] [Abstract][Full Text] [Related]
20. Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.
Cao L; Weetall M; Trotta C; Cintron K; Ma J; Kim MJ; Furia B; Romfo C; Graci JD; Li W; Du J; Sheedy J; Hedrick J; Risher N; Yeh S; Qi H; Arasu T; Hwang S; Lennox W; Kong R; Petruska J; Moon YC; Babiak J; Davis TW; Jacobson A; Almstead NG; Branstrom A; Colacino JM; Peltz SW
Mol Cancer Ther; 2019 Jan; 18(1):3-16. PubMed ID: 30352802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
